Revaprazan Hydrochloride
Revaprazan hydrochloride was approved by Korea Food and Drug Administration (KFDA) on September 1, 2005. It was developed and marketed as Revanex® by Yuhan Corporation in KR.
Revaprazan is the first acid pump antagonist with a function similar to that of proton pump inhibitors (PPIs). It has a dual action, active suppression of gastric acid secretion and gastric mucosa protection. It reduces gastric acid secretion which is used for the treatment of gastritis.
Revanex® is available as tablet for oral use, containing 100 or 200 mg of Revaprazan hydrochloride. The recommended dose is 200 mg orally once daily.
General Information
Update Date：2016-03-14
- Drug Name：
- Revaprazan Hydrochloride
- Research Code：
- SB-641257A; YH-1885
- Trade Name：
- Revanex®
- MOA：
- Proton pump inhibitor/PPI
- Indication：
- Gastric ulcer; Duodenal ulcer; Gastritis
- Status：
- Approved
- Company：
- Yuhan Corporation (Originator) , GlaxoSmithKline
- Sales：
- ATC Code：
Approved Countries or Area
Update Date：2015-07-29
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2005-09-01 | Marketing approval | Revanex | Gastric ulcer,Duodenal ulcer,Gastritis | Tablet | 100 mg/200 mg | Yuhan Corporation |
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 398.90 | ||||||||||||
| Formula | C22H24ClFN4 | |||||||||||||
| CAS No. |
199463-33-7 (Revaprazan ); 178307-42-1 (Revaprazan Hydrochloride); |
|||||||||||||
| Chemical Name | N-(4-Fluorophenyl)-4,5-dimethyl- 6-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidin-2-amine hydrochloride | |||||||||||||
| Revaprazan （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2016-01-27
